We try to get you to a lower dose where your weight is stable, youre not gaining weight back and youre continuing to benefit from the effects of these medications, says Dr
In addition, in recent years, a significant role has been attributed to coronary microvascular dysfunction as one of the pathogenetic factors for HFpEF progression
Code: WELCOME100 FSA & HSA accepted
Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism
However, it involves surgical risks
The starting dose and length of time to maintenance dose are critical to optimizing patient tolerability, Blai Coll, chief medical officer of Structure Therapeutics, told BioSpace